Citigroup Raises Quest Diagnostics (NYSE:DGX) Price Target to $145.00
Quest Diagnostics (NYSE:DGX – Free Report) had its target price boosted by Citigroup from $130.00 to $145.00 in a research report report published on Monday morning, Benzinga reports. They currently have a neutral rating on the medical research company’s stock. DGX has been the subject of a number of other research reports. JPMorgan Chase & […]
More Stories
Cadent Capital Advisors LLC Increases Holdings in Fidelity Total Bond ETF (NYSEARCA:FBND)
Cadent Capital Advisors LLC increased its position in Fidelity Total Bond ETF (NYSEARCA:FBND – Free Report) by 13.4% in the...
Bridge Creek Capital Management LLC Cuts Stock Holdings in Colgate-Palmolive (NYSE:CL)
Bridge Creek Capital Management LLC cut its holdings in shares of Colgate-Palmolive (NYSE:CL – Free Report) by 0.2% during the...
CHICAGO TRUST Co NA Purchases 1,299 Shares of RTX Co. (NYSE:RTX)
CHICAGO TRUST Co NA raised its position in RTX Co. (NYSE:RTX – Free Report) by 11.2% during the 4th quarter,...
Moody National Bank Trust Division Sells 380 Shares of Marathon Petroleum Co. (NYSE:MPC)
Moody National Bank Trust Division decreased its position in Marathon Petroleum Co. (NYSE:MPC – Free Report) by 2.6% during the...
CHICAGO TRUST Co NA Increases Stake in QUALCOMM Incorporated (NASDAQ:QCOM)
CHICAGO TRUST Co NA raised its stake in shares of QUALCOMM Incorporated (NASDAQ:QCOM – Free Report) by 12.6% during the...
CV Sciences (OTCMKTS:CVSI) and Blueprint Medicines (NASDAQ:BPMC) Head-To-Head Survey
CV Sciences (OTCMKTS:CVSI – Get Free Report) and Blueprint Medicines (NASDAQ:BPMC – Get Free Report) are both medical companies, but...